8-K: Assembly Biosciences Secures $12.6 Million in Equity Financings to Advance Antiviral Pipeline

Assembly Biosciences has raised approximately $12.6 million through separate equity financings with Armistice Capital and Gilead Sciences to support its antiviral drug development programs.

Summary

• Assembly Biosciences has secured approximately $12.6 million in gross proceeds through two separate equity financings.
• The financings involved the sale of common stock and warrants to Armistice Capital and Gilead Sciences.
• Armistice Capital purchased 634,500 shares and warrants for the same number of shares.
• Gilead Sciences purchased 179,500 shares and warrants for the same number of shares.
• The combined offering price was $15.46 per share and warrant.
• The warrants have an exercise price of $17.00 per share and expire on June 18, 2029.
• The company intends to use the net proceeds for general corporate purposes.
• The financing with Armistice Capital was a registered direct offering, while the financing with Gilead was a private placement.
• Assembly Bio and Gilead have also extended the time period to satisfy certain conditions related to Assembly Bios right to require Gilead to increase its ownership from 19.9 percent up to 29.9 percent of Assembly Bios outstanding voting stock at a premium.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful capital raise and continued collaboration with Gilead. However, the inherent risks associated with biotech development temper the overall optimism.

Positives

• The equity financings provide Assembly Biosciences with additional capital to support its operations.
• The investment from Gilead reinforces their commitment to the collaboration with Assembly Bio.
• The extension of the agreement with Gilead provides more time for potential future investment.

Risks

• The company's ability to realize the potential benefits of its collaboration with Gilead is subject to risks.
• Clinical studies may not be completed in the anticipated timeframes or at all.
• Safety and efficacy data from studies may not warrant further development of product candidates.
• Results of nonclinical studies may not be predictive of clinical outcomes.
• The company's future performance and clinical development plans are subject to risks and uncertainties.

Future Outlook

The company expects to use the net proceeds from the equity financings for general corporate purposes and anticipates near term interim data read outs including ABI-5366 Phase 1a in 3Q24 and Phase 1b in 1H25, and ABI-4334 Phase 1b by end of 2024.

Management Comments

• The Armistice and Gilead investments strengthen our balance sheet as we look to deliver important interim clinical data readouts expected by the end of the year and continue to advance our novel pipeline, said Jason Okazaki, chief executive officer and president of Assembly Bio.
• In addition, the amendment of our equity agreement terms with Gilead reflects our companies shared commitment to the advancement of our collaboration candidates in the coming years, with four candidates expected to be in clinic this year.

Industry Context

This announcement reflects a common strategy for biotech companies to raise capital to fund ongoing research and development. The involvement of Gilead, a major player in the antiviral space, highlights the potential of Assembly Bio's pipeline and the strategic importance of their collaboration.

Comparison to Industry Standards

• The use of registered direct offerings and private placements are standard methods for biotech companies to raise capital.
• The terms of the warrants, including the exercise price and expiration date, are typical for such financings.
• The extension of the agreement with Gilead is a positive sign of continued collaboration and potential future investment, which is common in the biotech industry.
• Comparable companies such as Vir Biotechnology and Arbutus Biopharma also utilize similar financing methods to fund their research and development.

Related Party Transactions

• The sale of common stock to Gilead maintains Gileads ownership of 19.9 percent of the outstanding voting stock of Assembly Bio as of the date of closing pursuant to the terms of the Investor Rights Agreement entered into between Assembly Bio and Gilead in October 2023.

Stakeholder Impact

• Shareholders will see dilution from the issuance of new shares.
• Employees will benefit from the company's increased financial stability.
• Customers (potential patients) may benefit from the advancement of the company's drug pipeline.
• Creditors may see increased confidence in the company's ability to meet its obligations.

Next Steps

• Assembly Bio will use the net proceeds for general corporate purposes.
• The company will continue to advance its antiviral pipeline.
• The company anticipates near term interim data read outs including ABI-5366 Phase 1a in 3Q24 and Phase 1b in 1H25, and ABI-4334 Phase 1b by end of 2024.
• Assembly Bio will file a registration statement with the SEC registering the resale of the shares of common stock issued to Gilead and the shares of common stock issuable upon exercise of the warrants issued to Gilead.

Key Dates

Keywords

equity financing, antiviral therapeutics, clinical development, Armistice Capital, Gilead Sciences, common stock, warrants, registered direct offering, private placement, capital raise